Skip to main navigation
Skip to search
Skip to main content
Experts@Minnesota Home
Home
Profiles
Research units
University Assets
Projects and Grants
Research output
Datasets
Press/Media
Activities
Fellowships, Honors, and Prizes
Impacts
Search by expertise, name or affiliation
Uterine serous carcinoma: Key advances and novel treatment approaches
J. Stuart Ferriss
,
Britt K. Erickson
, Ie Ming Shih
, Amanda N. Fader
Obstetrics, Gynecology and Women's Health - Gynecologic Oncology
Research output
:
Contribution to journal
›
Review article
›
peer-review
58
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Uterine serous carcinoma: Key advances and novel treatment approaches'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
% Response
16%
Actionable Target
16%
Advance Treatment
100%
Advanced Disease
16%
Advancing Age
16%
Black Women
16%
Breast Cancer Family History
16%
Cancer Mortality
16%
Cancer Subtypes
16%
CCNE1 Amplification
16%
Clinical Risk Factors
16%
Conventional Chemotherapy
16%
Endometrial Cancer
50%
ERBB2 Amplification
16%
FBXW7 mutation
16%
Gynecologic Malignancies
16%
HER2-positive
16%
HER2-targeted Therapy
16%
Hereditary Breast Ovarian Cancer Syndrome
16%
Histology
16%
Homologous Recombination
16%
Human Epidermal Growth Factor Receptor 2 (HER2)
16%
Improved Outcomes
16%
Improved Survival
16%
Incidence Rate
16%
Lenvatinib
16%
Molecular Drivers
16%
Molecular Genetic Analysis
16%
Mortality Rate
16%
Mutation Mutation
16%
Novel Treatments
100%
Overexpression
16%
Pembrolizumab
16%
Phase II Study
16%
PIK3CA mutation
16%
Plateaued
16%
Poor Prognosis
16%
PPP2R1A
16%
Recent Advances
16%
Recurrent Disease
16%
Somatic mutation
16%
Tailored Treatment
16%
Targeted Agents
16%
Targeted Therapeutics
16%
Targeted Treatment
16%
TP53 mutation
16%
Trastuzumab
16%
Treatment Options
16%
Uterine Serous Carcinoma
100%
Working Diagnosis
16%
Medicine and Dentistry
Breast Cancer
16%
Cancer
33%
Diseases
33%
Genetic Analysis
16%
Hereditary Breast-Ovarian Cancer Syndrome
16%
Homologous Recombination
16%
Lenvatinib
16%
Mortality Rate
16%
Pembrolizumab
16%
Recurrent Disease
16%
Somatic Mutation
16%
Tamoxifen
16%
Targeted Therapy
16%
Trastuzumab
16%
Treatment Option
16%
Uterine Cancer
50%
Uterine Serous Carcinoma
100%
Pharmacology, Toxicology and Pharmaceutical Science
Breast Cancer
16%
Carcinoma
100%
Chemotherapy
16%
Diseases
33%
Endometrium Cancer
50%
Lenvatinib
16%
Mortality Rate
16%
Ovary Cancer
16%
Pembrolizumab
16%
Recurrent Disease
16%
Syndrome
16%
Tamoxifen
16%
Trastuzumab
16%